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The inhibition of human mesangial cell proliferation by S-trans,
trans-farnesylthiosalicylic acid.
Background. Many of the proliferative cytokines implicated
in human mesangial cell (HMC) proliferation signal through
the superfamily of Ras GTPases. The Ras antagonist, S-trans,
trans- farnesylthiosalicylic acid (FTS), was used to investigate
the effects of the inhibition of Ras signaling on HMC prolifer-
ation.
Methods. Ras expression and membrane localization,
MAPK, and Akt activation were analyzed by Western blotting.
Ras activation was determined with a pull-down assay using the
Ras-binding domain of Raf. HMC growth curves were assessed
using the MTS assay of viable cell number, while DNA syn-
thesis was measured with BrdU incorporation. Hoechst 33342
staining was used to determine apoptosis.
Results. FTS reduced the membrane localization of Ras in
both serum and platelet-derived growth factor (PDGF). FTS
(7.5–20 lmol/L) potently inhibited PDGF-induced HMC pro-
liferation but had no effect on serum-induced proliferation. FTS
(10–20 lmol/L) inhibited both Ras and phospho-MAPK acti-
vation by serum and PDGF. Furthermore, FTS (10–20 lmol/L)
increased HMC apoptosis in the presence of PDGF but not in
serum. Moreover, PDGF-stimulated activation of the survival
protein Akt was inhibited by FTS. In contrast, serum-stimulated
activation of Akt was unaffected by FTS.
Conclusion. FTS (5–20 lmol/L) inhibits PDGF-induced but
not serum-induced HMC proliferation. FTS (10–20 lmol/L)
also promotes HMC apoptosis in the presence of PDGF but
not serum. These effects appear to be mediated by inhibitory
effects on Ras-dependent signaling that occur as a result of the
dislodgment of Ras from its membrane-anchorage sites by FTS.
The selectivity of FTS toward PDGF-driven HMC proliferation
suggests that FTS may be a valuable therapeutic in mesangio-
proliferative renal disease.
Aberrant human mesangial cell (HMC) prolifera-
tion plays a critical role in the pathogenesis and pro-
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gression of glomerular injury and glomerulosclerosis
[1]. Indeed, HMC proliferation is a hallmark of both
immune-mediated and non-immune–mediated glomeru-
lar injury [2]. In vivo studies have demonstrated that
MC proliferation precedes and correlates with increased
mesangial matrix production [3]. Furthermore, strategies
to inhibit MC proliferation, such as complement deple-
tion [4], and antibodies targeting platelet-derived growth
factor (PDGF) [5] and basic fibroblast growth factor
(bFGF) [6], have been shown to reduce mesangial ma-
trix production and sclerosis. Elucidating the cellular pro-
cesses that underlie HMC proliferation may lead to the
development of more effective therapies for mesangio-
proliferative disease.
A large number of cytokines, including PDGF, bFGF,
angiotensin II, endothelin, interleukin-1 (IL-1), and IL-6
have been implicated in the regulation of HMC prolif-
eration [7]. The intracellular signaling pathways of many
of these mitogens converge upon the Ras superfamily of
small monomeric GTPases [8], which act as molecular
switches, in the transduction of extracellular prolifera-
tive signals from the plasma membrane to the cell nu-
cleus. Within the Ras superfamily of proteins, Ras itself
plays a key role in regulating cell proliferation, apop-
tosis, and differentiation [8]. Once activated, Ras cycles
from an inactive, GDP-bound form to an active GTP-
bound form. GTP-bound Ras is then able to activate a
number of downstream effector cascades, of which the
Ras-Raf-Mitogen activated protein kinase (MAPK) cas-
cade is most strongly implicated in the control of cell
proliferation [8, 9].
Ras exists as three closely related isoforms known as
Harvey (Ha)-, Kirsten (Ki)-, and Neural (N)-Ras. Extra-
cellular signals that activate Ras can be mediated through
different types of receptors, such as receptor tyrosine
kinases (e.g., PDGF, bFGF), cytokine receptors, and G
protein–coupled receptors [10–12].
To transduce such growth signals, it is thought that Ras
must be anchored to the inner surface of the plasma mem-
brane [13]. To localize to the plasma membrane, Ras un-
dergoes a series of post-translational modifications. The
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first step, known as prenylation, involves the binding of
hydrophobic isoprenoid groups (farnesyl or geranylger-
anyl residues) to the cysteine (C) in the carboxy-terminal
CAAX motif (where A is an aliphatic acid and X is me-
thionine or serine) [14]. Prenylation of Ras is followed by
terminal amino acid (AAX) cleavage and methylation.
Ha-Ras and N-Ras then undergo palmitoylation before
translocating to the plasma membrane [15], while Ki-Ras
has a polybasic-domain consisting of a chain of six lysine
residues that act as a membrane targeting sequence [16].
S-trans, trans-farnesylthiosalicylic acid (FTS) is a syn-
thetic S-prenyl derivative of a rigid carboxylic acid that
structurally resembles the carboxy-terminal farnesylcys-
teine group common to prenylated Ras proteins [17].
FTS appears to act as a functional Ras antagonist by dis-
lodging Ras from specific membrane anchorage domains,
thereby inhibiting Ras-dependent signaling [18]. FTS has
been shown to inhibit the growth of Ha-Ras-transformed
Rat-1 cells [19], and Ki-Ras transformed rodent fibrob-
lasts in vitro [20]. As well as having potent antiprolifera-
tive effects in vitro, FTS has been shown to be effective
in vivo, not only in models of cancer [21], but also in
models of inflammatory disease, such as a rat model of
cirrhosis [22], and in a genetic model of systemic lupus
erythematosus (SLE) [23]. Recent work from our group
has demonstrated that FTS can inhibit glomerular cell
proliferation, proteinuria, and macrophage infiltration in
the rat Thy 1.1 nephritis model of MC proliferation [24].
This work examines the role of Ras in HMC prolif-
eration in vitro by using FTS to target Ras-dependent
signaling.
METHODS
Materials
All reagents and antibodies were purchased from
Sigma-Aldrich (Gillingham, UK) unless otherwise
stated. Stock solutions of FTS were made up in chloro-
form. Prior to experimental use, FTS was dissolved in
DMSO. U0126 was also made up in DMSO. Final DMSO
concentrations were 0.2%, including vehicle-only control
conditions.
Primary human mesangial cell culture
Primary culture HMC (Clonetics, Biowhittaker,
Wokingham, UK) were maintained in RPMI 1640 (Invit-
rogen Limited, Inchinnan, UK) medium with 10% fetal
calf serum (10% FCS). All experiments were carried out
between passages 4 and 9.
Western blotting
For Western blotting experiments, HMC were grown
to 80% confluence in 35- or 100-mm plates, in RPMI
1640 and 10% FCS. Cells were then serum-starved for
24 hours, and then treated overnight with FTS (0–
20 lmol/L) in media containing either 10% FCS or
PDGF-BB (200 ng/mL). Cells were lysed in cell-lysis
buffer, and equal amounts of protein lysate [25] were
immunoprecipitated with 15 lL of a rat anti-pan-Ras
antibody/agarose conjugate (clone Y13-259)/mL lysate
(Merck, Nottingham, UK) followed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and Western immnunoblotting with a pan-Ras mono-
clonal antibody (Merck) and an antimouse immunoglob-
ulin G (IgG) horseradish peroxidase conjuagate (Merck).
Protein expression was detected by Amersham ECL
chemiluminescence (Amersham Pharmacia Biotech,
Little Chalfont, UK).
Total cell membrane and total cytosol fractions were
obtained by suspending cell pellets in ice-cold hypotonic
lysis buffer, and centrifuging at 320g for 10 minutes to
clear debris, after which the supernatants were spun for
1 hour at 100,000g to separate membrane and cytosolic
fractions. Aliquots of lysate were then resuspended in
2X cell lysis buffer and left on ice for 30 minutes. Equal
volumes of lysate were then immunoprecipitated and Ras
detected as outlined before.
To determine MAPK and Akt activation, cells were
serum starved for 24 hours and then treated with FTS
(5–20 lmol/L) or vehicle for 4 hours in serum-free me-
dia. The cells were then stimulated for 5 to 10 minutes
with either PDGF (200 ng/mL) or 10% FCS. SDS-PAGE
and Western blotting were performed as before using a
Phospho-MAPK (Erk 1/2) or Phosph-Akt (Ser 473) anti-
body (New England Biolabs, Hitchin, UK). Separate im-
munoblots with equal amounts of cell lysate were probed
with primary antibodies for total MAPK (Erk1/2) and
total Akt (New England Biolabs).
Ras activation
Affinity precipitation using the Ras-binding domain
(RBD) of Ras was used to determine Ras activation. Nu-
clear material was removed by centrifugation, and lysates
were assayed for protein as above. Equal amounts of
cell protein (250–500 lg) were normalized for volume,
and 15 lL of Raf-RBD-GST-agarose (Upstate Biotech,
Botolph, UK) per mL of lysate were added. The sam-
ples were then rotated at 4◦C for 30 minutes, pelleted at
14,000g at 4◦C for 2 minutes, and washed twice in magne-
sium lysis buffer (MLB) and once in 50 mmol/L Tris pH
6.5. The samples were then heated to 100◦C for 3 minutes,
and the sepharose beads were removed by pulse centrifu-
gation for 10 seconds. The supernatants then underwent
SDS-PAGE and immunoblotting as above.
Cell proliferation
To study the effects of FTS on proliferation, HMC were
serum starved for 24 hours, trypsinized, and seeded in
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triplicate into 96-well plates at a density of 5000 cell/well,
which approximated to a confluence of 20% to 30%. FTS
(5–20 lmol/L) was then added and cells were grown in ei-
ther 10% FCS or 200 ng/mL of PDGF. Preliminary experi-
ments showed HMCs to be responsive to PDGF, and this
dose of PDGF gave optimal growth curves. Viable cell
numbers were determined by the MTS assay (Cell titer
96; Promega, Southampton, UK), measuring absorbance
at 490 nm.
DNA synthesis was assessed by Bromodeoxyuridine
(BrdU) uptake. Cells were grown in 35-mm dishes up
to a confluence of 90%, and serum starved for 24 hours
prior to treatment with FTS in the presence of either
PDGF (200 ng/mL) or 10% FCS. Six hours after the ad-
dition of FTS and growth factor, BrdU (10 lmol/L) was
added to each dish for 16 hours. Dishes were then washed
with phosphate-buffered saline (PBS), fixed (3 volume
50 mmol/L glycine and 7 volume ethanol), incubated in
4M hydrochloric acid for 10 minutes, washed 3 times in
PBS, and blocked in 5% goat serum/0.05%Tween/PBS
for 15 minutes before being incubated overnight in anti-
BrdU antibody (1 in 100 dilution) at 4◦C. BrdU-positive
cells were detected using a TRITC-labeled antimouse
IgG antibody (Sigma), and cell nuclei were counter-
stained with Hoechst 33342 (Sigma) at a concentration
of 5 lg/mL for 15 minutes. Cells were then visualized
with a fluorescent microscope. BrdU-positive cells stain
nuclei red, while all cell nuclei would stain blue. A total
of at least 150 cells were counted from at least 5 different
fields. Nuclei that appeared apoptotic on Hoechst stain-
ing were not counted.
Apoptosis
HMC were grown in 35-mm dishes and treated with
FTS as before. Hoechst 33342 was added (5 lg/mL), and
then incubated at 37◦C for 15 minutes followed by propid-
ium iodide (5 lmol/L) for 5 minutes. Cell nuclei were then
visualized under fluorescent microscopy. Apoptotic nu-
clei were then identified as showing characteristic signs of
chromatin condensation and fragmentation. Late apop-
totic or necrotic cells stained red. A total of at least 150
cells were counted from at least 5 different fields.
Statistics
Statistical analysis was performed using analysis of
variance (ANOVA) followed by Dunnett’s test of signif-
icance using Prism software (GraphPad, San Diego, CA,
USA).
RESULTS
PDGF-stimulated but not serum-stimulated HMC
growth is dependent on the Ras-Raf-MAPK pathway
The activation status of the Ras-Raf-MAPK pathway
was assessed by determining the phosphorylation sta-
tus of Erk 1 and Erk 2. UO126, a compound that in-
hibits the phosphorylation of Erk 1/2, was used to study
the role of this pathway in HMC proliferation. As can
be seen from Figure 1, UO126 (20 lmol/L) reduces the
phosphorylation of Erk 1/2 both in PDGF and in serum.
Figure 2 demonstrates that PDGF-stimulated growth
curves are inhibited by UO126 in a dose-dependent man-
ner. At 48 hours, UO126 (20 lmol/L) reduced cell number
by 67.5%. In contrast, UO126 (10–20 lmol/L) had no ef-
fect on cell number in serum at 48 hours. While we did
not perform cytotoxicity studies, higher doses of U0126
have been used in other cell models without evidence of
cytotoxicity [26].
FTS reduces membrane-localized but not total
cellular Ras
FTS had no effect on total cellular Ras expression in
both PDGF and serum (data not shown). When assessing
the membrane localization of Ras, 10 to 20 lL FTS caused
a significant reduction in the expression of membrane-
bound Ras, as shown in Figure 3. This effect was seen in
both PDGF and serum.
FTS inhibits HMC proliferation in PDGF but not
in serum
Figure 4 shows that FTS causes a marked dose-
dependent reduction in cell number in the presence of
PDGF. FTS 7.5 lmol/L reduces cell number by 13.6%
at 24 hours, and 30.4% at 48 hours when compared to
vehicle-treated cells. FTS 10 lmol/L reduces cell num-
ber by 70.7% at 24 hours, and by 89%% at 48 hours
when compared to vehicle-treated cells. At a dose of
20 lmol/L, FTS causes an even greater loss in cell number
at 24 and 48 hours. In marked contrast to the effects in
PDGF, serum-stimulated HMC growth curves were not
affected by FTS at doses of up to FTS 20 lmol/L. Indeed,
even when higher doses of FTS (50 lmol/L) were used
in the presence of serum, there was still no effect on cell
number at 48 hours (data not shown).
DNA synthesis was assessed by BrdU uptake, as shown
in Figure 5. BrdU-positive cells were detected using an
anti-BrdU antibody and a TRITC-labeled secondary an-
tibody. Only nuclei that incorporated BrdU stain red
when viewed with a fluorescent microscope. The total
number of nuclei was counterstained with Hoechst 33342,
and these appeared blue under fluorescence. Cells of
apoptotic morphology were not counted. Examples of
BrdU-positive nuclei are shown in Figure 5A and C. The
total number of nuclei in the same fields of view is shown
in Figure 5B and D. As can be seen in Figure 6A, 5 to
20 lmol/L FTS causes a dose-dependent reduction in
BrdU uptake in PDGF-stimulated cells. FTS 5 lmol/L
reduces BrdU uptake by 72.8%, and 7.5 lmol/L reduces
BrdU uptake by 83%. At doses of 10 to 20 lmol/L, FTS
reduces BrdU uptake by over 95%. In marked contrast,
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Fig. 1. (A) Western blot for phospho-MAPK (Erk 1/2) and total MAPK (Erk 1/2) in stimulated HMC after overnight treatment with the MEK
inhibitor U01026 (20 lmol/L) or vehicle (DMSO). Cells were then stimulated with 10% FCS or 200 ng/mL PDGF for 10 minutes as indicated. As
can be seen UO126 (20 lmol/L) inhibits the phosphorylation of Erk 1/2 by both serum and PDGF. (B) The effect of U0126 on relative Erk 1/2
activation as compared to stimulated HMCs as determined by densitometry. Error bars are SD, N = 6, ∗∗∗P < 0.001 with respect to vehicle-treated
cells.
5 to 20 lmol/L FTS has no effect on BrdU uptake in FCS-
stimulated cells (Fig. 6B).
FTS induces HMC apoptosis in PDGF but not serum
Figure 7 shows the effect of FTS on apoptosis in the
presence of PDGF and serum. When quantifying the de-
gree of apoptosis, it was apparent that FTS induced apop-
tosis in the presence of PDGF. Ten percent to 20% of
cells had apoptotic features after treatment with 10 to
20 lmol/L of FTS. In marked contrast, FTS had no
proapoptotic actions on HMC in the presence of serum,
even at doses of up to 20 lmol/L.
FTS inhibits Ras activation and Ras-dependent signaling
In order to establish whether dislodging Ras from the
plasma membrane had a functional effect on its signaling
activity, the RBD pull-down assay was used to investi-
gate the effects of FTS on Ras-GTP expression. As can
be seen in Figure 8, there is minimal basal active Ras in
serum-starved cells. Activation by PDGF for 5 minutes
greatly increased the amount of Ras pulled down by the
RBD-GST fusion protein. Furthermore, prior treatment
of HMC with 10 to 20 lmol/L FTS caused marked at-
tenuation of Ras activation by PDGF. Total cellular Ras
remained unchanged. FTS treatment also inhibited
serum-induced Ras activation.
The effect of FTS on signaling downstream of Ras
was determined by examining the activation of phospho-
Erk1/2. Figure 9 shows that 10 to 20 lmol/L FTS causes
marked inhibition of PDGF-induced and serum-induced
phosphorylation of Erk1/2. FTS had no effect on total
cellular Erk1/2 expression, suggesting that the reduction
in phospho-Erk1/2 is due to specific inhibition of phos-
phorylation, and not due to reductions in total cellular
Erk1/2.
Serum but not PDGF can activate AKT in the presence
of FTS
The effects of FTS on a second Ras effector cascade,
the PI 3-kinase pathway, were also studied. Activation
of this pathway results in the activation of the survival
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Fig. 2. (A) The inhibitory effect U01026 on
HMC growth curves in 200 ng/mL PDGF. Cell
number was then estimated using the MTS
assay by measuring the absorbance over 48
hours. Panel (B) shows that UO126 has no
inhibitory effect on cell number in 10% FCS.
The error bars are SD, N = 6. ∗∗P < 0.01 with
respect to vehicle-treated cells.
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Fig. 3. (A) Western blots for pan-Ras in cytosolic (C) and membrane (M) fractions of HMC treated for 24 hours with FTS. Cells were serum-starved
for 24 hours prior to incubation with FTS (5–20 lmol/L) for 24 hours in the presence of 200 ng/mL PDGF or 10% FCS. Cells were then lysed and
cytosolic and membrane fractions separated as described in methods. FTS reduced membrane-bound Ras in both growth factors. The ratio of M:C
Ras expression is shown in (B). The error bars are SD, N = 6. ∗P < 0.05 with respect to vehicle-treated cells.
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Fig. 4. Effects of FTS on HMC growth
curves. HMC were incubated with 200 ng/mL
of PDGF (A) or 10% FCS (B) in the pres-
ence of increasing concentrations of FTS (5–
20 lmol/L). Cell number was then estimated
using the MTS assay by measuring the ab-
sorbance over 48 hours. The error bars are
SD, N = 12. ∗∗P < 0.01 with respect to vehicle-
treated cells.
Vehicle-only treated HMC
FTS-treated HMC
A B
DC
Fig. 5. Example of double staining of FTS-
treated HMCs with BrdU and Hoechst 33342.
Selected fields are shown for illustration at
×20 magnification. The cells were treated with
FTS and incubated with either 10% FCS or
200 ng/mL PDGF for 24 hours. Cells stained
for BrdU as described in Methods. Panels
(A) and (B) show vehicle-treated HMC in the
presence of PDGF, while panels (C) and (D)
show HMC treated with FTS 10 lmol/L in
PDGF 200 ng/mL. BrdU-positive cells, which
stain red, are shown in panels (A) and (C),
while the total number of nuclei in the same
fields of view (stain blue) are shown in panels
(B) and (D).
protein Akt. Figure 10 shows that there is minimal basal
phospho-Akt expression, which is markedly up-regulated
by PDGF. FTS 5 lmol/L has no effect on PDGF-induced
activation of phospho-Akt, while 10 to 20 lmol/L FTS
completely inhibits the response to PDGF. These changes
in phospho-Akt expression do not appear to be a result
of reductions in total Akt. In contrast, serum is able to
activate Akt despite treatment with FTS (5–20 lmol/L).
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Fig. 6. BrdU incorporation in FTS treated
HMC. The percentage of BrdU-positive cells
is plotted 24 hours’ post-treatment with FTS
and stimulation with either 200 ng/mL PDGF
(A) or 10% FCS (B). Error bars are SD, N =
3. ∗∗∗P < 0.001 with respect to vehicle-treated
cells.
DISCUSSION
Growth factor production, MC proliferation, and
extracellular matrix production are key features of
mesangioproliferative and crescentic glomerulonephri-
tides. There is a considerable body of evidence to sug-
gest that PDGF is a key mesangial mitogen. PDGF can
stimulate MC proliferation in vitro [27], and plays a po-
tent pro-proliferative role in the rat anti-Thy-1.1 nephri-
tis model of mesangioproliferative disease [6]. In addi-
tion, there is increased expression of both PDGF and
PDGF-b receptor mRNA in glomeruli from patients with
mesangioproliferative diseases [28]. PDGF is also likely
to have an important role in mediating vascular and inter-
stitial injury in the kidney [29]. Ras GTPases act at a key
convergent point in the PDGF-stimulated cell signaling
pathways, suggesting that the targeting of Ras-signaling
pathways may lead to the development of novel therapies
for mesangioproliferative renal disease [30].
The inhibitory effect of UO126 on PDGF-stimulated
growth curves suggests that the Ras-Raf-MAPK
pathway plays a key role in PDGF-driven HMC pro-
liferation. Activation of Ras ultimately results in the
phosphorylation of Erk1/2, which then translocates
into the nucleus and induces mitogenesis through the
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Fig. 7. Effects of FTS on apoptosis as as-
sessed by Hoechst 33342 and PI staining. Per-
centage of cells showing apoptotic features in
the presence of PDGF (A) and 10% FCS (B) is
shown. Error bars are SD, N = 3. ∗∗∗P < 0.001
with respect to vehicle treated cells. Exam-
ples of nuclei stained with Hoechst 33342 af-
ter treatment with FTS 10lmol/L in the pres-
ence of either 10% FCS or 200 ng/mL PDGF.
Selected fields are shown for illustration at
×200 magnification. Apoptotic nuclei show
characteristic features of chromatin conden-
sation and cell shrinkage.
transcription of growth-related genes such as c-jun and
c-fos [10]. The lack of effect of UO126 on serum-
stimulated growth curves suggests that non-Ras-Raf-
MAPK signaling pathways are important in promoting
serum-induced cell proliferation. G-protein–coupled re-
ceptor (GPCR) agonists, such as lysophosphatidic acid
(LPA), are thought to account for much of the mitogenic
activity of serum [12]. LPA may activate a number of sig-
naling proteins that regulate cell transcription and prolif-
eration, including PI 3-kinase [31], the Jun kinases (JNK),
and possibly other members of the MAPK superfamily
such as p38, Erk 5, Erk 6, and SAPK4 [12].
FTS is a small molecule that targets the Ras-Raf-
MAPK signaling pathway. It dislodges activated, GTP-
bound Ras from cell membrane anchorage domains [18].
Recent work suggests that galectin-1 acts as a Ras-binding
protein, stabilizing the interactions between Ha-Ras (and
to a lesser extent, Ki-Ras) and the plasma membrane [32].
It is this interaction between galectin-1 and Ras that is dis-
rupted by FTS, though the precise mechanism of action of
FTS remains to be elucidated. The dose-dependent inhi-
bition in HMC of Ras membrane localization at concen-
trations by FTS (5–20 lmol/L) in both serum and PDGF
has been seen in a variety of cell types [20, 33].
The results presented here show the exquisite sensitiv-
ity of PDGF-driven HMC proliferation to FTS. Further-
more, these effects of FTS on PDGF-stimulated HMC
proliferation occur at doses that dislodge Ras from the
plasma membrane, inhibit the activation of Ras, and
down-regulate the activation of MAPK. These results
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Fig. 8. The effect of FTS on Ras activation, as determined by Ras-GTP expression, in HMC. Cells were serum starved, treated overnight with FTS
in serum-free media, prior to stimulation with PDGF 200 ng/mL and 10% FCS (A). As can be seen, FTS inhibits Ras activation by both PDGF and
10% FCS. Panel (B) demonstrates the effect of FTS on relative Ras activation as compared to stimulated HMCs, as determined by densitometry.
Error bars are SD, N = 5, ∗∗∗P < 0.001 with respect to vehicle-treated cells.
suggest that FTS inhibits PDGF-stimulated HMC pro-
liferation by suppressing the Ras-Raf-MAPK cascade.
These observations are consistent with previous findings
demonstrating that FTS can inhibit the activation of Ras
[32], and also inhibit MAPK activation [34]. The remark-
able sensitivity of PDGF-induced HMC proliferation to
FTS contrasts strikingly with the lack of effect of much
higher doses of FTS in serum. Even though FTS was still
able to inhibit the membrane localization and activation
of Ras in serum, it had no effect on serum-driven HMC
proliferation. Similar effects have been observed in ear-
lier work where FTS had no effect on serum-induced
proliferation of Rat-1 cells, while potently inhibiting
the proliferation of EGF- or FGF-stimulated prolifer-
ation [19]. Again, this suggests that serum can utilize
signaling pathways other than the Ras-Raf-MAPK cas-
cade. This hypothesis is consistent with our findings
that both UO126 and FTS fail to inhibit serum-induced
proliferation.
The effects of FTS on apoptosis appear to be partly
mediated by modulation of Akt activity. Akt is a ser-
ine/threonine kinase that lies downstream of the PI 3-
kinase, and provides a critical anti-apoptotic signal to
the cell [35]. The proapoptotic effects of FTS in PDGF
are associated with inhibition of the activation of the
survival factor Akt. In contrast, FTS does not prevent
serum-induced activation of Akt, and has no apoptotic
effect in the presence of serum. The activation of Akt
by serum in the presence of FTS suggests that mito-
gens, such as LPA, can activate the PI 3-kinase pathway
in a Ras-independent manner. LPA acting through G-
protein–coupled receptors has been shown to potently
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Fig. 9. Western blots for phospho-MAPK (Erk 1/2) and total MAPK (Erk 1/2) in stimulated HMC after overnight treatment with FTS and
stimulation with PDGF and 10% FCS (A). As can be seen, FTS (10–20 lmol/L) inhibits the phosphorylation of Erk 1/2 by both serum and PDGF.
Total Erk 1/2 remained unchanged. Panel (B) demonstrates the effect of FTS on relative Erk1/2 activation as compared to stimulated HMCs, as
determined by densitometry. Error bars are SD, N = 5. ∗∗∗P < 0.001 with respect to vehicle-treated cells.
activate the PI 3 kinase/Akt signaling pathway [36]. The
inhibition of PDGF-induced activation of Akt in HMC
by FTS suggests that direct activation of PI 3-kinase by
PDGF requires some active Ras to be present in the cells.
Thus, by inhibiting Ras activation, FTS prevents activa-
tion of PI 3-kinase. The proapoptotic effects of FTS have
also been observed in melanoma cells [37], although inter-
estingly, this effect was not dependent upon the inhibition
of Akt activation.
These data suggest that FTS-induced apotosis may
be rescued by serum activation of Akt. It is there-
fore possible that FTS may induce apoptosis of normal
quiescent HMCs in vivo. Clearly, further preclinical
toxicology studies are required to address this issue.
However, in an in vivo model of melanoma, FTS had no
effect on murine glomerular structure, suggesting that the
presence of growth factors or cell-cell interactions may
protect mesangial cells from the proapoptotic effects of
FTS in vivo [38].
Recent work from our group has shown that the in
vitro selectivity of FTS toward PDGF-stimulated HMC
proliferation has also been seen in rat mesangial cells
(RMCs) both in vitro and in vivo in the rat model of
Thy1.1 nephritis [24]. FTS markedly reduced glomeru-
lar cell proliferation and matrix expansion in this model.
Interestingly, RMC proliferation was associated with in-
creased glomerular expression of Ki-Ras and N-Ras, sug-
gesting that increased expression of these Ras isoforms
may be important in RMC proliferation in vivo. This
increase in Ras expression was almost completely pre-
vented by treatment with FTS, suggesting that the in
vivo effects of FTS may be mediated by modulating Ras
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Fig. 10. (A) Western blots analysis for phospho-Akt in FTS-treated cells stimulated with PDGF 200 ng/mL and 10% FCS. FTS inhibits activation
of phospho-Akt by PDGF but not by 10% FCS. Panel (B) shows the effect of FTS on relative Akt activation as determined by densitometry in
HMCs stimulated by PDGF (upper graph) and 10% FCS (lower graph). Error bars are SD, N = 3. ∗P < 0.05 and ∗∗∗P < 0.001 with respect to
vehicle-treated cells.
Khwaja et al: Farnesylthiosalicylic acid and human mesangial cell proliferation 485
expression. The current work in primary culture HMC
suggests that FTS may have a specific effect on PDGF-
driven mesangioproliferative human disease.
Targeting Ras with FTS appears to be a promising ther-
apeutic development. A number of other strategies that
can target Ras may also be of clinical value in prolifer-
ative renal disease [30]. These include the use of statins,
which inhibit the prenylation of Ras and Rho GTPases,
as well as newer compounds that target signals upstream
or downstream of Ras. For example, a Raf-1 antagonist
(BAY43-9006) is already undergoing clinical trials for the
treatment of cancer [9], while a small-molecule tyrosine
kinase inhibitor, currently being used as a novel treat-
ment of chronic myeloid leukemia [39], has been shown
to attenuate renal injury in the Thy 1.1 nephritis model
[40].
CONCLUSION
PDGF-stimulated HMC proliferation is dependent on
activation of the Ras-Raf-MAPK signaling pathway. FTS
inhibits the membrane localization of Ras, thereby down-
regulating Ras-dependent signaling pathways, inhibiting
cell proliferation, and promoting apoptosis. The speci-
ficity of FTS to PDGF-driven MC proliferation both in
vitro and in vivo suggests that it may be a promising new
therapy for the treatment of mesangioproliferative renal
disease.
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